The next generation immune checkpoint inhibitors and stimulators market is estimated to be worth USD 12.5 billion in 2030, predicts Roots Analysis

Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions

Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.
Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).
An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
An analysis of the partnerships that have been established in this domain, in the recent past.
A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
An analysis of the initiatives of big biopharma players engaged in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Lupus Nephritis
Melanoma
Multiple Myeloma
Primary Sjögren's Syndrome
Others
Target Immune Checkpoint
B7-H3
CD38
CD40
CD47
Others
Mechanism of Action
Inhibitory
Stimulatory
Therapeutic Modality
Monoclonal Antibody
Small Molecule
Type of Therapy
Monotherapy
Combination Therapy
Route of Administration
Intravenous
Subcutaneous
Others
Key Geographical Region
North America
Europe
Asia-Pacific and the Rest of the World

Key companies covered in the report
Bristol Myers Squibb
GlaxoSmithKline
Incyte
Novartis
Trillium Therapeutics

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

Other Recent Offerings
1. Neoantigen Targeted Therapies Market, 2019-2030
2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

This release was published on openPR.